Compugen Ltd. (CGEN) is a Biotechnology company in the Healthcare sector, currently trading at $2.89. It has a SharesGrow Score of 81/100, indicating a strong investment profile with 5 out of 7 criteria passed.
SharesGrow calculates the intrinsic value of CGEN = $5.39 (+86.5% from the current price, the stock appears undervalued). Analyst consensus target is CGEN = $4 (+38.4% upside).
Valuation: CGEN trades at a trailing Price-to-Earnings (P/E) of 6.3 (S&P 500 average ~25).
Financials: revenue is $73M, +163.5%/yr average growth. Net income is $35M, growing at +138.9%/yr. Net profit margin is 48.6% (strong). Gross margin is 87.3% (+0.3 pp trend).
Balance sheet: total debt is $3M against $103M equity (Debt-to-Equity (D/E) ratio 0.03, conservative). Current ratio is 6.56 (strong liquidity). Debt-to-assets is 1.9%. Total assets: $157M.
Analyst outlook: 12 / 13 analysts rate CGEN as buy (92%) — strong consensus.
SharesGrow 7-Criteria breakdown: Value 96/100 (Pass), Growth 100/100 (Pass), Past 25/100 (Fail), Health 100/100 (Pass), Moat 46/100 (Partial), Future 100/100 (Pass), Income 100/100 (Pass).
